Real-world usage, effectiveness, and microbiological features of ceftazidime-avibactam in clinical practice in China
Frontiers in Cellular and Infection Microbiology · 2026
DOI: 10.3389/fcimb.2025.1663392 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2026. Verfasst von Xiaohua Qin und 20 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Ceftazidime, Azabicyclo Compounds, Anti-Bacterial Agents, Gram-Negative Bacterial Infections. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Infections due to multidrug- and extensively drug-resistant bacteria can be difficult to treat and are associated with high mortality and burden of disease. Ceftazidime-avibactam (CVA) is used in patients with multidrug-resistant Gram-negative bacterial infections.
Objective
To describe the real-world usage, effectiveness, and antimicrobial features of CVA in clinical practice in China.
Methods
This multicenter, prospective observational study collected medical record data from adult patients (≥18 years) who had been hospitalized and treated with ≥1 dose of CVA. Clinical and microbiological outcomes were evaluated at the end of treatment, with clinical cure defined as resolution of infection following treatment with CVA.
Results
Data were obtained from 220 adult patients receiving ≥1 dose of CVA in China. Infections indicated for CVA included pneumonia (64.5%), complicated intra-abdominal infection (16.8%) and bloodstream infection (7.3%). Klebsiella pneumoniae (129/227 isolates, 56.8%) was the most commonly identified pathogen, followed by Pseudomonas aeruginosa (33 isolates, 14.5%). Of 87 K . pneumoniae isolates, 76 (87.4%) were meropenem resistant and the same proportion carried cabapenemase genes. Low levels of resistance to CVA were observed across all isolates. Three-quarters of patients received CVA as definitive therapy. Clinical cure at end of treatment was achieved in 66.4% of patients and microbiological success in 69.6% of patients.
Conclusion
Findings from this study provide important real-world data on treatment patterns, microbiological features, and clinical and microbiological outcomes for CVA in routine clinical practice in China.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
- Department of Infectious Diseases, The First Affiliated Hospital of Nanchang University, Nanchang, China.
- Department of Pulmonary and Critical Care Medicine, Henan Provincial People's Hospital, Zhengzhou, China.
- Department of Infectious Diseases, Beijing Tsinghua Changgung Hospital, Beijing, China.
- Department of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China.
- Department of Liver Diseases and Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Zitieren
APA
Qin, X., Xiang, T., Zhang, X., Ma, X., Zhao, W., Yu, Y., Zhao, C., Gao, L., Li, L., Wang, T., Pang, C., Zhao, X., Han, R., Cao, F., Su, M., Lu, J., Xu, W., Yin, S., Lu, D., …, & Wang, M. (2026). Real-world usage, effectiveness, and microbiological features of ceftazidime-avibactam in clinical practice in China. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2025.1663392
Vancouver
Qin X, Xiang T, Zhang X, Ma X, Zhao W, Yu Y, et al. Real-world usage, effectiveness, and microbiological features of ceftazidime-avibactam in clinical practice in China. Frontiers in Cellular and Infection Microbiology. 2026. doi:10.3389/fcimb.2025.1663392
BibTeX
@article{Qin2026,
author = {Qin, Xiaohua and Xiang, Tianxin and Zhang, Xiaoju and Ma, Xuzhu and Zhao, Weifeng and Yu, Yunsong and Zhao, Caiyan and Gao, Liang and Li, Lifen and Wang, Tiantian and Pang, Chongjie and Zhao, Xiaoyu and Han, Renru and Cao, Felix and Su, Ming and Lu, Junchao and Xu, Wenjuan and Yin, Shan and Lu, Danni and Yang, Xinyu and Wang, Minggui},
title = {Real-world usage, effectiveness, and microbiological features of ceftazidime-avibactam in clinical practice in China},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
doi = {10.3389/fcimb.2025.1663392}
}
EUVIMED